Kai Schulze

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8275720/publications.pdf

Version: 2024-02-01

29	1,024	394421 19	477307 29
papers	citations	h-index	g-index

29	29	29	1470
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Modeling Influenza Virus Infection: A Roadmap for Influenza Research. Viruses, 2015, 7, 5274-5304.	3.3	125
2	Bis-(3â€²,5â€²)-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine, 2011, 29, 5210-5220.	3.8	110
3	Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 711-722.	3.3	85
4	The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine, 2007, 25, 1464-1469.	3.8	75
5	Generation of HLA-Universal iPSC-Derived Megakaryocytes and Platelets for Survival Under Refractoriness Conditions. Molecular Medicine, 2016, 22, 274-285.	4.4	74
6	Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection. Npj Vaccines, 2017, 2, 9.	6.0	45
7	Intranasal Delivery of Influenza rNP Adjuvanted with c-di-AMP Induces Strong Humoral and Cellular Immune Responses and Provides Protection against Virus Challenge. PLoS ONE, 2014, 9, e104824.	2.5	43
8	Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice. Frontiers in Immunology, 2017, 8, 1223.	4.8	42
9	Neutral Lipopolyplexes for InÂVivo Delivery of Conventional and Replicative RNA Vaccine. Molecular Therapy - Nucleic Acids, 2019, 17, 767-775.	5.1	38
10	Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination. Journal of Controlled Release, 2015, 206, 140-152.	9.9	36
11	Self-replicating RNA vaccine functionality modulated by fine-tuning of polyplex delivery vehicle structure. Journal of Controlled Release, 2017, 266, 256-271.	9.9	36
12	Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2017, 11, e0005300.	3.0	31
13	Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids. Molecular Therapy - Nucleic Acids, 2018, 12, 118-134.	5.1	30
14	The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells. Vaccine, 2019, 37, 4963-4974.	3.8	30
15	The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization. Frontiers in Cellular and Infection Microbiology, 2019, 9, 31.	3.9	30
16	Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors. Scientific Reports, 2018, 8, 10146.	3.3	29
17	Type I IFN and not TNF, is Essential for Cyclic Di-nucleotide-elicited CTL by a Cytosolic Cross-presentation Pathway. EBioMedicine, 2017, 22, 100-111.	6.1	26
18	Intranasal vaccination with an adjuvanted polyphosphazenes nanoparticle-based vaccine formulation stimulates protective immune responses in mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2169-2178.	3.3	25

#	Article	IF	Citations
19	Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi. Frontiers in Immunology, 2020, 11, 128.	4.8	22
20	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. Journal of Hepatology, 2019, 70, 593-602.	3.7	20
21	Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2463-2474.	3.3	19
22	New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy. Current Topics in Microbiology and Immunology, 2016, 398, 207-234.	1.1	16
23	Self-Amplifying Pestivirus Replicon RNA Encoding Influenza Virus Nucleoprotein and Hemagglutinin Promote Humoral and Cellular Immune Responses in Pigs. Frontiers in Immunology, 2020, 11, 622385.	4.8	11
24	Rodents as pre-clinical models for predicting vaccine performance in humans. Expert Review of Vaccines, 2015, 14, 1213-1225.	4.4	9
25	Role of Autophagy in Von Willebrand Factor Secretion by Endothelial Cells and in the In Vivo Thrombin-Antithrombin Complex Formation Promoted by the HIV-1 Matrix Protein p17. International Journal of Molecular Sciences, 2020, 21, 2022.	4.1	7
26	Prophylactic Multi-Subunit Vaccine against Chlamydia trachomatis: In Vivo Evaluation in Mice. Vaccines, 2021, 9, 609.	4.4	4
27	Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development. Journal of Visualized Experiments, 2018, , .	0.3	3
28	Towards Reduction or Substitution of Cytotoxic DMSO in Biobanking of Functional Bioengineered Megakaryocytes. International Journal of Molecular Sciences, 2020, 21, 7654.	4.1	2
29	The FAI protein of group C streptococci acts as a mucosal adjuvant by the specific targeting and activation of B cells. International Journal of Medical Microbiology, 2008, 298, 3-10.	3.6	1